Skip to content

Bicuspid Aortic Valve Aortopathy

TL;DR — Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation, with a newborn echocardiographic prevalence of 4.6 per 1,000 live births and a striking male excess (7.1 vs 1.9 per 1,000; Tutar 2005, PMID 16169333), consistent with the conventional 1–2% population figure (Garg 2005, PMID 16025100). BAV is strongly heritable — h² of 89% for BAV alone in a family-based analysis (Cripe 2004, PMID 15234422) — and NOTCH1 mutations cause BAV with severe valve calcification in non-syndromic autosomal dominant pedigrees (Garg 2005, PMID 16025100). Ascending aortopathy is frequent: 49 of 384 BAV patients without a baseline aneurysm developed one over a mean 16 years, an incidence of 84.9 per 10,000 patient-years and an age-adjusted relative risk of 86.2 versus the general population (Michelena 2011, PMID 21917581). Dissection risk, by contrast, is low in absolute terms — 3.1 per 10,000 patient-years (2 events in 416 patients) — although the age-adjusted relative risk is 8.4. Causation is genuinely contested: valve fusion morphology dictates flow eccentricity, regional wall shear stress and the anatomical pattern of dilatation (Mahadevia 2014, PMID 24345403), and within-patient paired aortic samples show elastin degeneration and matrix dysregulation localised to high-shear regions (Guzzardi 2015, PMID 26293758) — yet high heritability and identified causal genes demand a genetic contribution. The reconciliation is unresolved and is the central open question of the field.

Prevalence and demography

BAV is the most common congenital heart lesion. Prospective transthoracic echocardiographic screening of 1,075 live-born neonates (567 male, 508 female; gestational ages 27–42 weeks) found BAV in 4.6 per 1,000 live births, with a marked sex difference (Tutar 2005, PMID 16169333):

Group BAV prevalence
All newborns 4.6 / 1,000
Male newborns 7.1 / 1,000
Female newborns 1.9 / 1,000

That is a male-to-female ratio of approximately 3.7:1. All BAV newborns were asymptomatic and only one had mild aortic regurgitation (Tutar 2005, PMID 16169333). Contemporaneous statements put population prevalence at 1–2% (Garg 2005, PMID 16025100) or ~1% (Cripe 2004, PMID 15234422); the newborn screening figure is lower than these, which is expected given that clinically ascertained series enrich for detected disease while some newborn valves may be classified differently later. BAV is a leading substrate for aortic valve stenosis and regurgitation and for infective endocarditis (Ward 2000, PMID 10618341).

In a community cohort of 416 Olmsted County residents with definite BAV diagnosed echocardiographically 1980–1999, a female-only subgroup analysis found median age at BAV diagnosis of 35 years (McKellar 2011, PMID 21146694).

Nomenclature and fusion phenotypes

The 2021 International Consensus Statement recognises three types of BAV (Michelena 2021, PMID 34304861):

  1. Fused type, with three phenotypes — right-left cusp fusion (RL), right-non cusp fusion (RN), and left-non cusp fusion (LN)
  2. Two-sinus type, with two phenotypes — latero-lateral and antero-posterior
  3. Partial-fusion (forme fruste)

The same consensus recognises three bicuspid-aortopathy types: ascending phenotype, root phenotype, and extended phenotypes (Michelena 2021, PMID 34304861). This vocabulary matters because the older literature used incompatible descriptors, and because fusion phenotype maps onto dilatation pattern.

Fusion phenotype and dilatation pattern. 4D-flow MRI in 75 subjects — 15 RL-BAV (mid ascending aorta 39.9 ± 4.4 mm), 15 RN-BAV (39.6 ± 7.2 mm), 30 tricuspid aorta-size controls (41.0 ± 4.4 mm), and 15 healthy volunteers (24.9 ± 3.0 mm) — found that eccentric outflow jets raised regional wall shear stress at the right-anterior wall in RL-BAV and the right-posterior wall in RN-BAV (p < 0.0125 vs size-matched controls). Aortopathy type differed sharply by fusion morphology: dilatation of the aortic root only (type 1) or involving the entire ascending aorta and arch (type 3) occurred in 87% of RN-BAV patients but was mostly absent in RL-BAV patients, of whom 87% were type 2. These differences were associated with altered flow displacement — a 42–81% decrease in the proximal and mid ascending aorta for type 1 versus type 2, and a 33–39% increase in the distal ascending aorta for type 3 versus type 2 (Mahadevia 2014, PMID 24345403).

Frequency of associated aortopathy

The community cohort quantifies how often the aorta dilates. Of 384 BAV patients without a baseline aneurysm, 49 developed one during follow-up (mean 16 ± 7 years; 6,530 patient-years total for the full cohort), an incidence of 84.9 per 10,000 patient-years (95% CI 63.3–110.9) and an age-adjusted relative risk of 86.2 (95% CI 65.1–114; p < 0.001) versus the general county population. The 25-year rate of aortic surgery was 25% (95% CI 17.2–32.8) (Michelena 2011, PMID 21917581).

In the female subgroup, of 60 women with serial echocardiograms a median 10.7 years apart, 21 (35%) had an aorta > 40 mm at follow-up and 2 had > 50 mm, versus 5 (6%) > 40 mm and 1 > 50 mm at initial diagnosis — a significant rate of progressive enlargement warranting longitudinal follow-up (McKellar 2011, PMID 21146694).

Dissection risk: BAV vs tricuspid vs Marfan

This is where BAV is most often misrepresented. The relative risk is high; the absolute risk is low.

Population / subgroup Aortic dissection incidence (per 10,000 patient-years)
BAV cohort, diagnosed (2 events / 416 patients) 3.1 (95% CI 0.5–9.5)
BAV irrespective of diagnosis status (incl. 2 undiagnosed cases) 1.5 (95% CI 0.4–3.8)
BAV, aged ≥ 50 y at baseline 17.4 (95% CI 2.9–53.6)
BAV, aneurysm present at baseline 44.9 (95% CI 7.5–138.5)

Age-adjusted relative risk of dissection versus the general population was 8.4 (95% CI 2.1–33.5; p = 0.003) (Michelena 2011, PMID 21917581). The authors' own conclusion was that over a mean 16 years of follow-up the incidence of aortic dissection was low, but significantly higher than in the general population.

Two comparisons put this in proportion:

  • Versus aneurysm development in the same cohort. The age-adjusted RR for developing an aneurysm was 86.2, an order of magnitude above the RR of 8.4 for dissecting (Michelena 2011, PMID 21917581). BAV is far more reliably a dilating aorta than a dissecting one.
  • Versus syndromic aortopathy. Loeys-Dietz syndrome had a mean age at death of 26.0 years in its founding series (Loeys 2006, PMID 16928994), and 23% of the 441-patient Montalcino TGFBR1/2 registry sustained an aortic dissection (Jondeau 2016, PMID 27879313). Marfan syndrome carried a median survival of 48 years even in 1972 (Silverman 1995, PMID 7810492). BAV's 2-events-in-416-patients does not belong in that risk class. Treating BAV with syndromic thresholds over-operates.

Pregnancy. Pregnancy and BAV are both considered dissection risk factors, but in an Olmsted County cohort of 88 women with BAV covering 216 pregnancies and 186 deliveries there were no aortic dissections, and pregnancy was not associated with aortic dilatation, aortic surgery or aortic valve replacement (McKellar 2011, PMID 21146694). Aortic dissection in women with BAV and pregnancy is rare in the community.

Genetics of BAV

Heritability. In 50 BAV probands with three-generation family histories and echocardiography of first-degree relatives (309 probands and relatives participating), BAV was identified in 74 individuals — a within-family prevalence of 24%, versus ~1% in the population — and BAV and/or another cardiovascular malformation in 97 (31%), including aortic coarctation, ventricular or atrial septal defect, abnormal mitral valve, aortic root dilation, or hypoplastic left heart syndrome. Maximum-likelihood variance decomposition gave heritability (h²) of 89% for BAV and 75% for BAV and/or other cardiovascular malformations (Cripe 2004, PMID 15234422). The authors concluded that in this population BAV determination is almost entirely genetic. This is the single strongest quantitative argument that BAV is not simply an acquired or stochastic developmental event.

NOTCH1. Mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal dominant human pedigrees. Notch1 transcripts were most abundant in the developing mouse aortic valve, and Notch1 repressed the activity of Runx2, a central transcriptional regulator of osteoblast cell fate; Hrt family repressors activated by Notch1 signalling physically interacted with Runx2 and repressed its transcriptional activity independent of histone deacetylase activity. The proposed model is a two-stage mechanism — an early developmental defect in valve formation, followed by later de-repression of calcium deposition causing progressive valve disease (Garg 2005, PMID 16025100).

NOTCH1 in BAV with aneurysm. A targeted mutational analysis of NOTCH1 exons previously implicated in BAV, using genomic DNA from 48 unrelated patients with concomitant BAV and thoracic aortic aneurysm undergoing surgical repair, found 4 unique non-synonymous variants (3 novel) in 5 of 48 patients (10.4%), versus 3 of 144 controls (2.1%; p = 0.02). Controls comprised tricuspid valves (n = 94), BAV with normal aortas (n = 22), and tricuspid valves with thoracic aortic aneurysm (n = 28). Two novel missense mutations, A1343V and P1390T, were observed only in patients with BAV and aneurysm (McKellar 2007, PMID 17662764). The overrepresentation is real but the effect size is modest — NOTCH1 explains a minority of BAV aortopathy.

Other genes. MAT2A rare variants were identified through whole-genome linkage and exome sequencing of a large family with autosomal dominant thoracic aortic aneurysm variably associated with the bicuspid aortic valve; the c.1031A>C (p.Glu344Ala) variant segregated with disease and a second family carried c.1067G>A (p.Arg356His), with zebrafish rescue experiments supporting impaired MAT IIα function (Guo 2015, PMID 25557781). BAV also co-occurs with Turner syndrome — see syndromic aortopathies.

Family screening. The heritability data have a direct operational consequence. Echocardiographic screening of first-degree relatives of 50 BAV probands found BAV in 24% of participants — roughly a 24-fold enrichment over the ~1% population prevalence — and BAV and/or another cardiovascular malformation in 31%, the additional lesions including aortic coarctation, ventricular or atrial septal defect, abnormal mitral valve, aortic root dilation and hypoplastic left heart syndrome (Cripe 2004, PMID 15234422). Screening a BAV proband's first-degree relatives therefore has a high yield, and the target of screening is broader than the valve: the associated malformation spectrum means a normal aortic valve in a relative does not close the question. This contrasts with the molecular cascade screening used in Mendelian HTAD, where a proband's identified variant converts relatives to a single definitive test — see genetics of TAA. Because most BAV heritability is not attributable to any identified gene, BAV family screening remains imaging-based rather than genotype-based.

The hemodynamic-versus-genetic debate

Both positions are supported by direct evidence, which is why the debate persists.

Evidence for hemodynamic causation.

  • Flow patterns track fusion morphology and dilatation pattern. Eccentric systolic outflow jets produce fusion-specific regional wall shear stress elevations (right-anterior in RL-BAV, right-posterior in RN-BAV), and aortopathy type differs by fusion phenotype (87% of RN-BAV type 1 or 3; 87% of RL-BAV type 2). The authors described these as "hemodynamic markers suggest[ing] a physiological mechanism by which the valve morphology phenotype can influence phenotypes of BAV aortopathy" (Mahadevia 2014, PMID 24345403).
  • Within-patient paired sampling localises tissue damage to high-shear regions. Twenty BAV patients undergoing ascending aortic resection had preoperative 4D-flow CMR to map WSS regionally, and paired aortic wall samples from elevated-WSS and normal-WSS regions in the same patient were compared. High-WSS regions showed greater medial elastin degradation — decreased total elastin (p = 0.01), thinner fibres (p = 0.00007), fibres farther apart (p = 0.001) — and matrix dysregulation: increased TGF-β1 (p = 0.04), MMP-1 (p = 0.03), MMP-2 (p = 0.06), MMP-3 (p = 0.02) and TIMP-1 (p = 0.04) (Guzzardi 2015, PMID 26293758). The within-patient design is what makes this evidence strong: genotype is held constant across the comparison, so the difference cannot be genetic.

Evidence for genetic causation.

  • Heritability of 89% for BAV alone (Cripe 2004, PMID 15234422) — a figure implying BAV determination is almost entirely genetic in that population.
  • Identified Mendelian genes. NOTCH1 mutations produce BAV in non-syndromic autosomal dominant pedigrees (Garg 2005, PMID 16025100), and NOTCH1 variants are overrepresented specifically in BAV patients who develop aneurysm (10.4% vs 2.1%; McKellar 2007, PMID 17662764).
  • Co-segregation of BAV with familial TAA. MAT2A variants segregated in a family with thoracic aortic aneurysm variably associated with BAV (Guo 2015, PMID 25557781), implying shared genetic determination of valve and aorta.
  • The clinical-practice argument. Suspected genetic causes of ECM dysregulation in the BAV ascending aorta have directly influenced strategies and thresholds for surgical resection — i.e. the genetic hypothesis has been operationalised into practice (Guzzardi 2015, PMID 26293758).

Status: unresolved. The two bodies of evidence are not straightforwardly contradictory. Heritability of the valve is compatible with hemodynamics of the aortopathy: genes could determine the valve morphology, which then determines the flow field, which then determines where and how the aorta degenerates. Under that reading, BAV aortopathy is genetically initiated and hemodynamically executed, and the practical question becomes whether the flow field is sufficient to explain the aortopathy or whether an independent intrinsic aortic wall defect is also present. The paired-sample study argues that the flow field is at minimum a substantial contributor (Guzzardi 2015, PMID 26293758), while the persistence of aortopathy phenotypes and the 89% heritability figure argue it is not the whole story (Cripe 2004, PMID 15234422). No study yet reported here resolves it. Guzzardi's authors called for validation of 4D-flow CMR as a non-invasive biomarker of disease progression and its ability to individualise resection strategies — the practical form the question takes.

See hemodynamics and biomechanics for wall shear stress methodology and pathophysiology for ECM degradation mechanisms.

Surveillance and threshold implications

The evidence above constrains management without settling it. Three points follow directly and are developed on the dedicated pages — this section deliberately does not duplicate them.

  1. Aneurysm development is common; dissection is not. Age-adjusted RR 86.2 for aneurysm versus 8.4 for dissection in the same cohort (Michelena 2011, PMID 21917581) argues for surveillance imaging rather than aggressive prophylactic resection. Progressive enlargement over a decade is documented (McKellar 2011, PMID 21146694), so surveillance must be longitudinal.
  2. Risk concentrates in identifiable subgroups. Dissection incidence rises from 3.1 to 17.4 per 10,000 patient-years in those aged ≥ 50 at baseline and to 44.9 in those with a baseline aneurysm (Michelena 2011, PMID 21917581). Threshold policy should be conditioned on these, not applied uniformly.
  3. Fusion phenotype predicts where the aorta dilates, and therefore what to image and potentially what to resect (Mahadevia 2014, PMID 24345403); the consensus nomenclature exists precisely to make this reportable (Michelena 2021, PMID 34304861).

Diameter criteria, indexed measures and class/level-of-evidence recommendations are covered in risk stratification and size thresholds and guidelines. Imaging modality choice and measurement conventions are in imaging and surveillance.

Open questions

  • Is BAV aortopathy hemodynamically caused, genetically caused, or sequential? Within-patient paired sampling shows elastin degradation and matrix dysregulation localised to high-WSS regions (Guzzardi 2015, PMID 26293758), while heritability of BAV is 89% (Cripe 2004, PMID 15234422). No design yet reported separates the intrinsic wall defect from the flow-imposed one.
  • Can 4D-flow WSS mapping individualise resection? This was proposed as warranting further study (Guzzardi 2015, PMID 26293758) and has not been validated as a prospective decision variable against clinical endpoints.
  • What explains the majority of BAV genetics? NOTCH1 variants were found in 10.4% of BAV-with-aneurysm patients versus 2.1% of controls (McKellar 2007, PMID 17662764) — leaving most of an 89%-heritable trait (Cripe 2004, PMID 15234422) genetically unexplained.
  • Are current BAV surgical thresholds calibrated to the actual dissection risk? Absolute dissection incidence is 3.1 per 10,000 patient-years while the 25-year aortic surgery rate is 25% (Michelena 2011, PMID 21917581); whether that operative burden is proportionate has not been formally evaluated.
  • Why do RL and RN fusion produce different aortopathy distributions? RN-BAV patients were 87% type 1 or type 3 while RL-BAV were 87% type 2 (Mahadevia 2014, PMID 24345403), an association demonstrated but not mechanistically explained, and derived from 15 patients per group.
  • Should pregnancy in BAV be managed as elevated risk at all? No dissections occurred across 216 pregnancies in 88 BAV women, and pregnancy was not associated with aortic dilatation (McKellar 2011, PMID 21146694) — yet BAV plus pregnancy is conventionally treated as a risk combination.

References

  1. Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J. 2005;150:513-5. PMID 16169333
  2. Ward C. Clinical significance of the bicuspid aortic valve. Heart. 2000;83:81-5. PMID 10618341
  3. Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol. 2004;44:138-43. PMID 15234422
  4. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-4. PMID 16025100
  5. McKellar SH, Tester DJ, Yagubyan M, et al. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007;134:290-6. PMID 17662764
  6. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306:1104-12. PMID 21917581
  7. McKellar SH, MacDonald RJ, Michelena HI, et al. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. Am J Cardiol. 2011;107:96-9. PMID 21146694
  8. Mahadevia R, Barker AJ, Schnell S, et al. Bicuspid aortic cusp fusion morphology alters aortic three-dimensional outflow patterns, wall shear stress, and expression of aortopathy. Circulation. 2014;129:673-82. PMID 24345403
  9. Guzzardi DG, Barker AJ, van Ooij P, et al. Valve-related hemodynamics mediate human bicuspid aortopathy: insights from wall shear stress mapping. J Am Coll Cardiol. 2015;66:892-900. PMID 26293758
  10. Michelena HI, Della Corte A, Evangelista A, et al. Summary: International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes. Ann Thorac Surg. 2021;112:1005-1022. PMID 34304861
  11. Guo DC, Gong L, Regalado ES, et al. MAT2A mutations predispose individuals to thoracic aortic aneurysms. Am J Hum Genet. 2015;96:170-7. PMID 25557781
  12. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788-98. PMID 16928994
  13. Jondeau G, Ropers J, Regalado E, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016;9:548-558. PMID 27879313
  14. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75:157-60. PMID 7810492